Bela Denes joins Clarus as CMO
This article was originally published in Scrip
Executive Summary
Clarus Therapeutics, a privately-held Illinois-based biopharma with an oral T replacement product, CLR-610, in Phase III, has appointed Dr Bela Denes chief medical officer. Dr Denes was most recently senior medical director at Abbott Laboratories, and has over 35 years of urology experience.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.